GOTHENBURG, Sweden, Sept. 20, 2011 /CNW/ - Cellectricon appoints David
Burns as the company's Chief Executive Officer. David brings a solid
and highly impressive international Life Science executive track record
to Cellectricon vital for the company's continued market expansion in
bringing state-of-the-art screening solutions for drug discovery and
David Burns has extensive experience of the life sciences industry and
has held executive management positions at Renishaw Diagnostics Ltd.,
Cyntellect Inc., GE Healthcare, Imaging Research Inc, BioSignal Packard
Inc., and Pharmacia / LKB Ltd. Significantly; Mr. Burns has previously
developed several companies through to outstanding commercial success.
Cellectricon's Chairman Axel Broms said: "The board is delighted with the appointment of David as the new
CEO. We are looking forward to working with him in formulating and
broadening the product offering using the Company's strong IP and
technology position. David's experience in both research instruments
and service businesses complements Cellectricon's strategic aim to
deliver more value to its customers by offering assay development
services based on Cellectricons in-house technology expertise in
addition to instrument sales."
David Burns added: "Cellectricon is a remarkable company with strong customer
validation and well-earned reputation for providing groundbreaking
products and services to the pharmaceutical and biotechnology
industries. I will focus on providing strategic, operational, and
customer relationship continuity. This will ensure that our customers
can depend on Cellectricon to accelerate their drug discovery and
biological research by continued development of new products and
services, as well as an outstanding customer support. "
Cellectricon AB, Sweden, is a leading life sciences solutions provider
of advanced screening products and services to accelerate drug
discovery and cell-based assay research. The company is a total
solutions provider of customized instruments to discovery services
solving critical bottlenecks in drug discovery & cell based research.
The proprietary technologies include industry leading platforms for
high resolution ion-channel screening, and cell engineering. Developed
in close collaboration with leaders in the pharmaceutical industry and
esteemed research labs, the Cellaxess®HT System enables high throughput
transfection for genomic screening and the new Dynaflow®HT System
greatly advances ion channel drug discovery.
SOURCE Cellectricon AB
For further information:
Susanne Fagerlund, VP Market Communications, Phone: +46(0)733-67-35-15, E-mail: email@example.com; David Burns, CEO, E-mail: firstname.lastname@example.org; Axel Broms, Chairman of the Board, E-mail: email@example.com